- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03810443
Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension (HYPER2)
January 17, 2019 updated by: Assistance Publique - Hôpitaux de Paris
Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension.
The hyperventilation syndrome is a frequent cause of dyspnea in general population and in respiratory diseases like asthma but has never been studied in pulmonary hypertension.
The goal of this study is to measure the prevalence of pulmonary hypertension in a population of patients with controlled pulmonary arterial hypertension (PAH).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Hyperventilation syndrome has been described as a cause of dyspnea in the general population and in several chronic respiratory diseases such as asthma with 20 to 40% of asthmatics affected.
However, Hyperventilation syndrome has never been sought in a population with PAH.
Hyperventilation syndrome, although complex pathophysiology, may be simply corrected by a management of respiratory physiotherapy based on the control of respiration.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Etienne-Marie JUTANT, CCA
- Phone Number: 01 45 21 78 91
- Email: etiennemarie.jutant@aphp.fr
Study Locations
-
-
-
Le Kremlin-Bicêtre, France, 94270
- Hôpital Bicêtre - Pneumology department
-
Contact:
- Etienne-Marie JUTANT, CCA
- Phone Number: 01 45 21 78 91
- Email: etiennemarie.jutant@aphp.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Non smoker or tobacco stopped for minimum 2 years ans maximum 10 year-pack. - Idiopathic, heritable, related to drug or toxics, associated with controlled pulmonary hypertension. Diagnosis and treatment of pulmonary hypertension for more than 4 months.
- Optimal control of pulmonary hypertension (no right heart failure symptom and NTproBNP < 300ng/L or Brain Natriuretic Peptide(BNP) < 50 ng/L and optimal hemodynamic results measured by a right heart catheterization in the last year: right atrial pressure < 8 mmHg, cardiac index > 2,5 L/min/m2, veinous saturation in oxygen > 65%)
- Informed and written consent
- Non-affiliation to a social security
Exclusion Criteria:
- Existence of another form of pulmonary hypertension
- Existence of vocal cord dysfunction
- Pregnancy
- Obesity> stage 2 (BMI 35 kg / m2)
- Age ≥ 75 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pulmonary arterial hypertension
The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
|
The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of the hyperventilation syndrome
Time Frame: 18 months
|
Prevalence of the hyperventilation syndrome in a population with pulmonary arterial hypertension
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
anxiety-depression questionary score
Time Frame: 18 months
|
results of anxiety-depression questionary
|
18 months
|
dyspnea score
Time Frame: 18 months
|
results of dyspnea questionary
|
18 months
|
quality of life score
Time Frame: 18 months
|
results of quality of life questionary
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Etienne-Marie JUTANT, CCA, APHP
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 14, 2019
Primary Completion (Anticipated)
July 14, 2021
Study Completion (Anticipated)
July 14, 2021
Study Registration Dates
First Submitted
December 20, 2018
First Submitted That Met QC Criteria
January 17, 2019
First Posted (Actual)
January 18, 2019
Study Record Updates
Last Update Posted (Actual)
January 18, 2019
Last Update Submitted That Met QC Criteria
January 17, 2019
Last Verified
December 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP180352
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Hyperventilation test
-
University of ZurichCompletedHyperventilation | Head Injury TraumaSwitzerland
-
Centre Hospitalier Universitaire Saint PierreUniversité Libre de Bruxelles; Hopitaux Iris SudCompletedHyperventilation SyndromeBelgium
-
Université Libre de BruxellesWithdrawnCognitive DysfunctionBelgium
-
Centre Hospitalier Metropole SavoieRecruitingHealthy | Pulmonary Disease, Chronic Obstructive | Pulmonary Arterial Hypertension | Lung Diseases, Interstitial | Chronic Heart Failure | Hyperventilation SyndromeFrance
-
Eysz, Inc.National Institute of Neurological Disorders and Stroke (NINDS)RecruitingSeizures | Absence Epilepsy | Epilepsy in Children | Absence Seizures | Absence Epilepsy, Childhood | StaringUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Persistent Asthma | Hyperventilation Syndrome | Difficult AsthmaFrance
-
University of LeicesterCompletedHemorrhage | Blood Pressure | Stroke, Acute | Cerebral Brain HemorrhageUnited Kingdom
-
Tampere University HospitalCompletedCerebral Metabolism and PerfusionFinland
-
Jordan University of Science and TechnologyCompletedLaparoscopic Gastric Sleeve Surgery | ASA-I and II Risk Class Patients | Same SurgeonJordan
-
Sahlgrenska University Hospital, SwedenCompleted